摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(benzo[d]thiazol-7-ylamino)-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino)pyrimidine-5-carboxamide | 1198302-71-4

中文名称
——
中文别名
——
英文名称
4-(benzo[d]thiazol-7-ylamino)-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino)pyrimidine-5-carboxamide
英文别名
4-(1,3-Benzothiazol-7-ylamino)-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidine-5-carboxamide
4-(benzo[d]thiazol-7-ylamino)-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino)pyrimidine-5-carboxamide化学式
CAS
1198302-71-4
化学式
C24H25N7O2S
mdl
——
分子量
475.574
InChiKey
OQXLCMMHDDKOGR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    34
  • 可旋转键数:
    9
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    147
  • 氢给体数:
    3
  • 氢受体数:
    9

文献信息

  • [EN] 2, 6-DIAMINO-PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS<br/>[FR] 2, 6-DIAMINO-PYRIMIDIN- B-YL-CARBOXAMIDES SERVANT D'INHIBITEURS DE Syk KINASES ET DE JANUS KINASES
    申请人:PORTOLA PHARM INC
    公开号:WO2009145856A1
    公开(公告)日:2009-12-03
    The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as cardiovascular disease, inflammatory disease, autoimmune disease and cell proliferative disorder, thrombosis, allergy, asthma, rheumatoid arthritis, leukemia, or non-Hodgkin's lymphoma.
    本发明涉及式I-II的化合物及其药学上可接受的互变异构体、盐或立体异构体,这些化合物是syk和/或JAK激酶的抑制剂。本发明还涉及用于制备这类化合物的中间体,制备这种化合物,含有这种化合物的药物组合物,抑制syk和/或JAK激酶活性的方法,抑制血小板聚集的方法,以及预防或治疗由syk和/或JAK激酶活性至少部分介导的多种疾病的方法,如心血管疾病、炎症性疾病、自身免疫疾病和细胞增殖障碍、血栓形成、过敏、哮喘、类风湿关节炎、白血病或非霍奇淋巴瘤。
  • Inhibitors of protein kinases
    申请人:Bauer Shawn M.
    公开号:US20090318407A1
    公开(公告)日:2009-12-24
    The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
    本发明涉及式I-II化合物及其药学上可接受的互变异构体、盐或立体异构体,其是SYK和/或JAK激酶的抑制剂。本发明还涉及用于制备这种化合物的中间体,该化合物的制备,含有该化合物的制药组合物,抑制SYK和/或JAK激酶活性的方法,抑制血小板聚集的方法,以及预防或治疗由SYK和/或JAK激酶活性至少部分介导的多种疾病,如不良血栓和非霍奇淋巴瘤的方法。
  • INHIBITORS OF PROTEIN KINASES
    申请人:Bauer Shawn M.
    公开号:US20120129867A1
    公开(公告)日:2012-05-24
    The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
    本发明涉及式I-II化合物及其药学上可接受的互变异构体、盐或立体异构体,其为syk和/或JAK激酶的抑制剂。本发明还涉及用于制备这种化合物的中间体,制备这种化合物的方法,包含这种化合物的制药组合物,抑制syk和/或JAK激酶活性的方法,抑制血小板聚集的方法,以及预防或治疗至少部分由syk和/或JAK激酶活性介导的多种情况的方法,例如不良血栓形成和非何杰淋巴瘤。
  • 2, 6-DIAMINO-PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS
    申请人:Portola Pharmaceuticals, Inc.
    公开号:EP2321283A1
    公开(公告)日:2011-05-18
  • US8138339B2
    申请人:——
    公开号:US8138339B2
    公开(公告)日:2012-03-20
查看更多

同类化合物

(1Z)-1-(3-乙基-5-羟基-2(3H)-苯并噻唑基)-2-丙酮 齐拉西酮砜 齐帕西酮-d8 阳离子蓝NBLH 阳离子荧光黄4GL 锂2-(4-氨基苯基)-5-甲基-1,3-苯并噻唑-7-磺酸酯 铜酸盐(4-),[2-[2-[[2-[3-[[4-氯-6-[乙基[4-[[2-(硫代氧代)乙基]磺酰]苯基]氨基]-1,3,5-三嗪-2-基]氨基]-2-(羟基-kO)-5-硫代苯基]二氮烯基-kN2]苯基甲基]二氮烯基-kN1]-4-硫代苯酸根(6-)-kO]-,(1:4)氢,(SP-4-3)- 铜羟基氟化物 钾2-(4-氨基苯基)-5-甲基-1,3-苯并噻唑-7-磺酸酯 钠3-(2-{(Z)-[3-(3-磺酸丙基)-1,3-苯并噻唑-2(3H)-亚基]甲基}[1]苯并噻吩并[2,3-d][1,3]噻唑-3-鎓-3-基)-1-丙烷磺酸酯 邻氯苯骈噻唑酮 西贝奈迪 螺[3H-1,3-苯并噻唑-2,1'-环戊烷] 螺[3H-1,3-苯并噻唑-2,1'-环己烷] 葡萄属英A 草酸;N-[1-[4-(2-苯基乙基)哌嗪-1-基]丙-2-基]-2-丙-2-基氧基-1,3-苯并噻唑-6-胺 苯酰胺,N-2-苯并噻唑基-4-(苯基甲氧基)- 苯酚,3-[[2-(三苯代甲基)-2H-四唑-5-基]甲基]- 苯胺,N-(3-苯基-2(3H)-苯并噻唑亚基)- 苯碳杂氧杂脒,N-1,2-苯并异噻唑-3-基- 苯甲酸,4-(6-辛基-2-苯并噻唑基)- 苯甲基2-甲基哌啶-1,2-二羧酸酯 苯并噻唑正离子,2-[3-(1,3-二氢-1,3,3-三甲基-2H-吲哚-2-亚基)-1-丙烯-1-基]-3-乙基-,碘化(1:1) 苯并噻唑正离子,2-[2-[4-(二甲氨基)苯基]乙烯基]-3-乙基-6-甲基-,碘化 苯并噻唑正离子,2-[(2-乙氧基-2-羰基乙基)硫代]-3-甲基-,溴化 苯并噻唑啉 苯并噻唑三氯金(III) 苯并噻唑-d4 苯并噻唑-7-乙酸 苯并噻唑-6-腈 苯并噻唑-5-羧酸 苯并噻唑-5-硼酸频哪醇酯 苯并噻唑-4-醛 苯并噻唑-4-乙酸 苯并噻唑-2-磺酸钠 苯并噻唑-2-磺酸 苯并噻唑-2-磺酰氟 苯并噻唑-2-甲醛 苯并噻唑-2-甲酸 苯并噻唑-2-甲基甲胺 苯并噻唑-2-基磺酰氯 苯并噻唑-2-基甲基-乙基-胺 苯并噻唑-2-基叠氮化物 苯并噻唑-2-基-邻甲苯-胺 苯并噻唑-2-基-己基-胺 苯并噻唑-2-基-(4-氯-苯基)-胺 苯并噻唑-2-基-(4-氟-苯基)-胺 苯并噻唑-2-基-(4-乙氧基-苯基)-胺 苯并噻唑-2-基-(2-甲氧基-苯基)-胺 苯并噻唑-2-基-(2,6-二甲基-苯基)-胺